|Articles|June 1, 1998

June 1998 - Special Issue
Volume 4
Issue 1 SP

Cancer Carve Outs, Specialty Networks, and Disease Management: A Review of Their Evolution, Effectiveness, and Prognosis

Download PDF: Cancer Carve Outs, Specialty Networks, and Disease Management: A Review of Their Evolution, Effectiveness, and Prognosis

Articles in this issue

about 28 years ago

Article

Carve Outs: Definition, Experience, and Choice Among Candidate Conditions

about 28 years ago

Article

Behavioral Health Services: Carved Out and Managed

about 28 years ago

Article

Massachusetts Medicaid and the Community Medical Alliance: A New Approach to Contracting and Care Delivery for Medicaid-Eligible Populations with AIDS and Severe Physical Disability

about 28 years ago

Article

Carve Outs and Related Models of Contracting for Specialty Care: Framework and Highlights of a Workshop

about 28 years ago

Article

Carve Outs: Comments on the Workshop

about 28 years ago

Article

The Economic Functions of Carve Outs in Managed Care

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Cancer Carve Outs, Specialty Networks, and Disease Management: A Review of Their Evolution, Effectiveness, and Prognosis

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year